Drug Resistance in Multiple Myeloma: Novel Therapeutic Targets Within the Malignant Clone

References

• Barlogie B., Epstein J., Selvanayagam P., Alexanian R. Plasma cell myeloma - New biological insights and advances in therapy. Blood 1989; 73: 865–879
   PubMed Web of Science ®Google Scholar
• Greipp P.R. Advances in the diagnosis and management of myeloma. Sem. Hematol. 1992; 29: 24–45
   PubMed Web of Science ®Google Scholar
• Grogan T.M., Spier C.M., Salmon S.E., Matzner M., Rybski J., Weinstein R.S., Scheper R.J., Dalton W.S. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490–495
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Lokhorst H.M., Vossebeld P. Drug resistance in multiple myeloma. Semin. Hematol. 1997; 34: 34–39
   PubMed Web of Science ®Google Scholar
• Pilarski L.M., Belch A.R. Circulating monoclonal B cells expressing p-glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma. Blood 1994; 83: 724–736
   PubMed Web of Science ®Google Scholar
• Pilarski L.M., Szczepek A.J., Belch A.R. Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma. Blood 1997; 90: 3751–3759
   PubMed Web of Science ®Google Scholar
• Abbaszadegan M.R., Futscher B.W., Klimecki W.T., List A., Dalton W.S. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res. 1994; 54: 4676–4679
   PubMed Web of Science ®Google Scholar
• Rome L., Kerdersha N., Chugani D. Unlocking vaults: organelles in search of a function. Trends in Cell Biol. 1991; 1: 47–50
   PubMedGoogle Scholar
• Kickhoefer V.A., Vasu S.K., Rome L. Vaults are the answer, what is the question?. Trends in Cell Biol 1996; 6: 174–178
   PubMed Web of Science ®Google Scholar
• Raaijmakers H.G., Izquierdo M.A., Lokhorst H.M., de Leeuw C., Belien J.A., Bloem A.C., Dekker A.W., Scheper R.J., Sonneveld P. Lung resistance protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998; 91: 1029–1036
   PubMed Web of Science ®Google Scholar
• Bergsagel D.E. Treatment of plasma cell myeloma. Ann. Rev. Med. 1979; 30: 431–433
   PubMed Web of Science ®Google Scholar
• Palmer M., Belch A., Hanson J., Brox L. Reassessment of the relationship between M-protein decrement and survival in multiple myeloma. Br. J. Cancer 1989; 59: 110–112
   PubMed Web of Science ®Google Scholar
• Attal M., Harosseau J.-L., Stoppa A.-M., Sotto J.-J., Fuzibet J.-G., Rossi J.-F., Cassasus P., Maisonneuve H., Facon T., Ifrah N., Payen C., Batialle R. A prospective, ramdomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Eng. J. of Medi. 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Pilarski L.M., Masellis S., Szczepek A., Mant M.J., Belch A.R. Circulating clonotypic B cells in the biology of myeloma. Speculations on the origin of multiple myeloma. Leuk. Lymphoma 1996; 22: 375–383
   PubMed Web of Science ®Google Scholar
• Szczepek A.J., Bergsagel P.L., Axelsson L., Brown C.B., Belch A.R., Pilarski L.M. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ rearrangements. Blood 1997; 89: 1824–1833
   PubMed Web of Science ®Google Scholar
• Berenson J., Wong R., Kim K., Brown N., Lichtenstein A. Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood 1987; 70: 1550–1553
   PubMed Web of Science ®Google Scholar
• Jensen G.S., Mant M.J., Belch A.R., Berensen J.R., Ruether B.A., Pilarski L.M. Selective expression of CD45 isoforms defines CALLA+ monoclonal B lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 1991; 78: 711–719
   PubMed Web of Science ®Google Scholar
• Billadeau D., Quam L., Thomas W., Kay N.E., Greipp P., Kyle R., Oken M.M., Van Ness B. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992; 80: 1818–1824
   PubMed Web of Science ®Google Scholar
• Billadeau D., Van Ness B., Kimlinger T., Kyle R.A., Therneau T.M., Greipp P.R., Witzig T.E. Clonal circulating cells are common in plasma cell proliferative disorders: A comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 1996; 88: 289–296
   PubMed Web of Science ®Google Scholar
• Corradini P., Voena C., Astolfi M., Ladetto M., Tarella C., Boccadoro M., Pilieri A. High dose sequential chemotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and After autografting. Blood 1995; 85: 1596–1602
   PubMed Web of Science ®Google Scholar
• Takashita M., Kosaka M., Goto T., Saito S. Cellular origin and extent of clonal involvement in multiple myeloma: genetic and phenotypic studies. Brit. J. Haematol. 1994; 87: 735–742
   PubMed Web of Science ®Google Scholar
• Corradini P., Voena C., Omede P., Astolfi M., Boccadoro M., Dalla-Favera R., Pilieri A. Detection of circulating tumor cells in multiple myeloma by a PCR based method. Leukemia 1993; 7: 1879–1882
   PubMed Web of Science ®Google Scholar
• Dreyfus F., Melle J., Quarre C., Pillier C. Contamination of peripheral blood by monoclonal B cells following treatment of multiple myeloma by high dose chemotherapy. Brit. J. Hematol. 1993; 85: 411–412
   PubMed Web of Science ®Google Scholar
• Bergsagel P.L., Masellis S., Szczepek A., Mant M.J., Belch A.R., Pilarski L.M. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56 and monotypic immunoglobulin light chain. Blood 1995; 85: 436–447
   PubMed Web of Science ®Google Scholar
• Szczepek AJ, Seeberger K., Wizniak J., Mand MJ, Belch AR, Pilavski LM. A high frequency of circulating B cells shave clonotypic IsH UDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in situ RT-PCR. 1998, BLOOD, impress
   Google Scholar
• Pilarski L.M., Yatscoff R.W., Murphy G., Belch A.R. Drug resistance in multiple myeloma: Cyclosporin analogues and metabolites as chemosensitizers. Leukemia 1998; 12: 505–509
   PubMed Web of Science ®Google Scholar
• Pilarski L.M., Jensen G.S. Monoclonal circulating B cells in multiple myeloma: A continuously differentiating possibly invasive population as defined by expression of CD45 isoforms and adhesion molecules. Hematol. Oncol. Clinics of North America 1992; 6: 297–322
   PubMed Web of Science ®Google Scholar
• Masellis-Smith A., Belch A.R., Mant M.J., Turley E.A., Pilarski L.M. Hyaluronan-dependent motility of B cells and leukemic plasma cells but not of bone marrow plasma cells in multiple myeloma: Alternate usage of RHAMM and CD44. Blood 1996; 87: 1891–1899
   PubMed Web of Science ®Google Scholar
• Pilarski L.M., Belch A.R. Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma; Implications for treatment. Leuk. Lymphoma 1995; 17: 367–374
   PubMed Web of Science ®Google Scholar
• Bakkus M.H.C., Van I., Riet B., Van Camp, Thielemann K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Brit. J. Hematol. 1994; 87: 68–74
   PubMed Web of Science ®Google Scholar
• Vescio R.A., Cao J., Hong C.H., Lee J.C., Wu C.H., Der Danielian M., Wu V., Newman R., Lichtenstein A., Berensen J.R. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutastion but no intraclonal diversity. J. Immunol. 1995; 155: 2487–2497
   PubMed Web of Science ®Google Scholar
• Sahota S.S., Leo R., Hamblin T., Stevenson F.K. Myeloma VL and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells. Blood 1997; 89: 219–226
   PubMed Web of Science ®Google Scholar
• Sahota S.S., Leo R., Hamblin T., Stevenson F.K. Ig VH gene mutation patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. Blood 1996; 87: 746–755
   PubMed Web of Science ®Google Scholar
• Jensen G.S., Belch A.R., Mant M.J., Ruether B.A., Yacyshyn B.R., Pilarski L.M. Expression of multiple beta-1 integrins on circulating monoclonal B cells in patients with multiple myeloma. Am. J. Hematol. 1992; 43: 29–36
   Web of Science ®Google Scholar
• Jensen G.S., Belch A.R., Kherani F., Mant M.J., Ruether B.A., Pilarski L.M. Restricted expression of immunoglobulin light chain mRNA and of the adhesion molecule CD11b on circulating monoclonal B lineage cells in peripheral blood of myeloma patients. Scand. J. Immunol. 1992; 36: 843–853
   PubMed Web of Science ®Google Scholar
• Kimlinger T., Witzig T.E. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma. Bone Marrow Transp. 1997; 19: 553
   PubMed Web of Science ®Google Scholar
• Vescio R.A., Hong C.H., Cao J., Kim A., Schiller G.J., Lichtenstein A.K., Berenson R.J., Berenson J.R. The hematopoietic stem cell antigen CD34 is not expressed on the malignant cells in multiple myeloma. Blood 1994; 84: 3283–3290
   PubMed Web of Science ®Google Scholar
• Turley E.A., Belch A.R., Poppema S., Pilarski L.M. Expression and function of a receptor for hyaluronan-mediated motility(RHAMM) on normal and malignant B lymphocytes. Blood 1993; 81: 446–453
   PubMed Web of Science ®Google Scholar
• Masellis S., Belch A.R., Mant M.J., Pilarski L.M. Adhesion of multiple myeloma peripheral blood B cells to bone marrow fibroblasts: a requirement for CD44 and α4β7. Cancer Res. 1997; 57: 930–936
   PubMed Web of Science ®Google Scholar
• Jensen G.S., Mant M.J., Pilarski L.M. Sequential maturation stages of monoclonal B lineage cells from blood, spleen, lymph node and bone marrow from a terminal myeloma patient. Am. J. Hematol. 1992; 41: 199–208
   PubMed Web of Science ®Google Scholar
• Pilarski L.M., Masellis Smith A., Belch A.R., Yang B., Savani R.C., Turley E.A. RHAMM, a receptor for hyaluronan-mediated motility, on normal lymphocytes, thymocytes and in B cell malignancy: A mediator in B cell malignancy? Leuk. Lymphoma 1994; 14: 363–374
   PubMed Web of Science ®Google Scholar
• Pilarski L.M., Mant M.J., Belch A.R. Circulating, monoclonal, multi-drug resistant B cells may comprise the malignant stem cells population in multiple myeloma. Challenges in Modern Medicine. Eds. F. Dammaco and B. Barlogie 1994; 4: 31–39
   Google Scholar
• Pilarski L.M., Szczepek A.J., Mant M.J., Belch A.R. Cryptic expression of the CD19 epitope detected by mAb Leu 12 distinguishes malignant from residual polyclonal B cells in the blood of myeloma patients. Blood. 1897, in press: (Abstract)
   Google Scholar
• Pilarski L.M., Ruether B.A., Mant M.J. Abnormal function of B lymphocytes from peripheral blood of multiple myeloma patients. I. Lack of correlation between the number of cells potentially able to secrete IgM and serum IgM levels. J. Clin. Invest. 1985; 75: 2024–2029
   PubMed Web of Science ®Google Scholar
• Pilarski L.M., Andrews E.J., Mant M.J., Ruether B.A. Humoral immune deficiency in multiple myeloma patients due to compromised B cell function. J. Clin. Immunol. 1986; 6: 491–501
   PubMed Web of Science ®Google Scholar
• Kay N.E., Leong T., Kyle R.A., Greipp P., Billadeau D., Van Ness B., Bone N., Oken M.M. Circulating blood B cells in multiple myeloma: analysis and relationship in circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern cooperative oncology group Phase III E9486 clinical trial. Blood 1997; 90: 340–345
   PubMed Web of Science ®Google Scholar
• Dalton W.S., Grogan T.M., Meltzer P.S., Scheper R.J., Durie B.G.M., Taylor C.W., Miller T.P., Salmon S.E. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of p-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 1989; 7: 415–424
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Durie B.G.M., Lokhorst H.M., Marie J.P., Solbu G., Suciu S., Zittroun R., Lowenberg B., Nooter K., Suzuki N., Sakane T., Tsunematsu T. Modulation of multidrug-resistant multiple myeloma by cyclosporin Effects of a novel immunosuppressive agent, FK506, on human B cell activation. Lancet 1992; 340: 255–259
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Marie J.P., Lokhorst H.M., Nooter K., Schoester M. Clinical modulation of multidrug resistance in VAD-refractory myeloma: studies with cyclosporin and SDZ PSC 833. Anti-Cancer Drugs 1994; 5 (Supl 1): 72
   Google Scholar
• Endicott J.A., Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. Ann. Rev. Biochem. 1989; 58: 137–171
   PubMed Web of Science ®Google Scholar
• Twentyman P.R. Modification of multidrug resistance. Brit. J. Hematol. 1995; 90: 735–737
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Marie J.P., Huisman C., Vekhoff A., Schoester M., Faussat A.M., van Kapel J., Groenewegen A., Charnick S., Zittoun R., Lowenberg B. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, docrubicin, dexamethasone) in refractory myeloma. A phase I study. Leukemia 1996; 10: 1741–1750
   PubMed Web of Science ®Google Scholar
• Borst P. Genetic mechanisms of drug resistance. Rev. Oncol. 1991; 4: 87–105
   Google Scholar
• Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Duncan A.M., Deeley R.G. Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 1992; 258: 1650–1654
   PubMed Web of Science ®Google Scholar
• Chaudhary P.M., Mechetner E.B., Roninson I.B. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 2735–2739
   PubMed Web of Science ®Google Scholar
• Klimecki W.T., Futscher B.W., Grogan T.M., Dalton W.S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451–2458
   PubMed Web of Science ®Google Scholar
• Pilarski L.M., Paine D., McElhaney J.M., Cass C.E., Belch A.R. The multidrug transporter, p-glycoprotein 170, on normal human lymphocytes and thymocytes: modulation with differentiation stage and during ageing. Am. J. Hematol. 1995; 49: 323–335
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Durie B.G.M., Lokhorst H.M., Frutiger Y., Schoester M., Vela E.E. Analysis of multidrug resistance (mdr-1) p-glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma. Brit. J. Hematol. 1993; 83: 63–67
   PubMed Web of Science ®Google Scholar
• Corneilssen J.J., Sonneveld P., Schoester M., Raaijmakers H.G., Nieuwenhuis H.K., Dekker A.W., Lokhorst H.M. MDR-1 expression and response to vincristine, doxrubicin and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J. Clin. Oncol. 1994; 12: 115–119
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Schoester M., de Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma: effects of cyclosporine on resistant tumor cells. J. Clin. Oncol. 1994; 12: 1584–1591
   PubMed Web of Science ®Google Scholar
• Latreille J., Barlogie B.A., Dosik G.A., Johnson D.A., Drewinko B., Alexanian R. Cellular DNA content as a marker of human multiple myeloma. Blood 1980; 55: 81–90, 403–408: –
   Web of Science ®Google Scholar
• Morgan, Jr., Gonchoroff N.J., Katzmann J.A., Witzig T.E., Kyle R.A., Greipp P.R. Detection of hypodiploidy using multi-parameter flow cytometric analysis: A prognostic indicator in multiple myeloma. Am. J. Hematol. 1989; 30: 195–200
   PubMed Web of Science ®Google Scholar
• Tienhaara A., Pelliniemi T.T. Flow cytometric DNA analysis and clinical correlations in multiple myeloma. Am. J. Clin. Pathol. 1992; 97: 322–330
   PubMed Web of Science ®Google Scholar
• Tsuchiya H., Welhamepstein J., Selvanayagam P., Dedman J.R., Gallick G., Alexanian R., Barlogie B. Correlated flow cytometric analysis of Ha-ras p21 and nuclear DNA in multiple myeloma. Blood 1988; 72: 796–800
   PubMed Web of Science ®Google Scholar
• Tafuri A., Meyers J., Lee B.J., Andreeff M. DNA and RNA flow cytometric study in multiple myeloma. Cancer 1991; 67: 449–454
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R., Orfao A., Gonzalez M., Moro M.J., Hernandez J.M., Ortega F., Borrego D., Camero M., Casanova F., Jimenez R., Portero J.A., San Miguel J.F. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Brit. J. Haematol. 1995; 90: 106–112
   PubMed Web of Science ®Google Scholar
• Haraldsdottir V., Haanen C., Kalsbeek-Batenburg E., Olthuis F. S-phase cells of the lymphoplasmocytic compartment in hyperdiploid multiple myeloma are diploid cells. Cytometry 1995; 21: 203–210
   PubMedGoogle Scholar
• Hall C.L., Yang X., Zhang S., Turley M., Samuel S., Savani R.C., Greenberg A.H., Turley E.A. Overexpression of the hyaluronan receptor RHAMM is transforming, and is required for H-ras transformation. Cell 1995; 82: 19–28
   PubMed Web of Science ®Google Scholar
• Cunningham A.J., Pilarski L.M. Antibody diversity: A case for its generation after antigenic stimulation. Scand. J. Immunol. 1974; 3: 5–10
   PubMed Web of Science ®Google Scholar
• Pilarski L.M., Cunningham A.J. Generation of antibody diversity III. Variation in the specificity of antibody produced within single clones of antibody forming cells in vitro. Eur. J. Immunol. 1974; 4: 762–767
   PubMed Web of Science ®Google Scholar
• Pilarski L.M., Cunningham A.J. Generation of antibody diversity IV. Variation within single clones of antibody forming cells developing in vivo. Eur. J. Immunol. 1975; 5: 10–16
   PubMed Web of Science ®Google Scholar